KRAS and cancer: At the clinical level, mutation of KRAS occurs in nearly 30% of all cancers and thus provides a clear target for diagnostics and targeted therapies.11 The most common mutation in KRAS is at codon 12, which in the wild type (WT) protein is occupied by a glycine (G) residue.